Canada’s Drug Agency | Drugs, Health Technologies and Systems.

durvalumab

Details

Generic Name:
durvalumab
Project Status:
Pending
Therapeutic Area:
Gastric or gastroesophageal junction adenocarcinoma
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0427-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable GC/GEJC.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 7, 2025